



BRIAN SANDOVAL
Governor

STATE OF NEVADA
DEPARTMENT OF HEALTH AND HUMAN SERVICES
DIVISION OF HEALTH CARE FINANCING AND POLICY
1100 E. William Street, Suite 101
Carson City, Nevada 89701
www.dhcfp.nv.gov

Richard Whitley
Interim Director
LAURIE SQUARTSOFF
Administrator

NOTICE OF OPEN PUBLIC MEETING

The Division of Health Care Financing and Policy (DHCFP) Pharmacy and Therapeutics Committee will conduct a public meeting on **June 25, 2015**, beginning at **1:00 p.m.** at the following location:

South Point Casino/Hotel
9777 Las Vegas Blvd. S.
Las Vegas, NV 89183

This meeting will be held only in Las Vegas, NV, there will be no teleconference to Carson City, NV.

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Robyn Heddy at: 775-684-3678 or email robyn.heddy@dhcfp.nv.gov in advance, but no later than two working days prior to the meeting, so that arrangements may be conveniently made.

Items may be taken out of order.

Items may be combined for consideration by the public body.

Items may be pulled or removed from the agenda at any time.

Public comment is limited to 5 minutes per individual, organization, or agency, but may be extended at the discretion of the Chairperson.

AGENDA

- I. CALL TO ORDER AND ROLL CALL
- II. PUBLIC COMMENT

No action may be taken on a matter raised under this item of the agenda until the matter itself has been specifically included on the agenda as an item upon which action can be taken.

- III. **FOR POSSIBLE ACTION**: Review and Approval of the March 26, 2015 Meeting Minutes
- IV. STATUS UPDATE BY DHCFP
 - A. Public Comment

B. Program Updates

V. NEW DRUG CLASSES

A. INJECTABLE AGENTS USED TO TREAT OPIOID OVERDOSE

1. Public Comment
2. Drug Class Review Presentation – Catamaran
3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

B. LONG ACTING OPIOIDS – ABUSE DETERRENT AGENTS

1. Public Comment
2. Drug Class Review Presentation – Catamaran
3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

C. ANTILIPEMICS – OMEGA-3 FATTY ACIDS

1. Public Comment
2. Drug Class Review Presentation – Catamaran
3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

VI. ESTABLISHED DRUG CLASSES

A. ANTIPSYCHOTICS: ORAL, ATYPICAL

1. Public Comment
2. Drug Class Review Presentation – Catamaran

3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

VII. ESTABLISHED DRUG CLASSES BEING REVIEWED DUE TO THE RELEASE OF NEW DRUGS.

A. ANTICOAGULANTS - ORAL

1. Public Comment
2. Drug Class Review Presentation – Catamaran
3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

B. Diabetic Agents: SGLT-2 INHIBITORS

1. Public Comment
2. Drug Class Review Presentation – Catamaran
3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

C. RESPIRATORY ANTIINFLAMMATORY AGENTS – RESPIRATORY CORTICOSTEROIDS

1. Public Comment
2. Drug Class Review Presentation – Catamaran
3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

- D. TOPICAL ANTIFUNGAL (ONYCHOMYCOSIS) AGENTS
 - 1. Public Comment
 - 2. Drug Class Review Presentation – Catamaran
 - 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
 - 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

- E. PHOSPHATE BINDING AGENTS
 - 1. Public Comment
 - 2. Drug Class Review Presentation – Catamaran
 - 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
 - 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

- F. INJECTABLE AGENTS FOR MULTIPLE SCLEROSIS
 - 1. Public Comment
 - 2. Drug Class Review Presentation – Catamaran
 - 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
 - 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

- VIII. REPORT BY CATAMARAN ON NEW DRUGS TO MARKET, NEW GENERIC DRUGS TO MARKET, AND NEW LINE EXTENSIONS

- IX. REVIEW OF NEXT MEETING LOCATION, DATE, AND TIME
 - A. September 24, 2015

- X. PUBLIC COMMENT

- XI. ADJOURNMENT

This notice and agenda has been posted on or before 9:00 a.m. on the third working day before the meeting at the following locations:

Notice of this meeting will be available on or after the posting date of this Agenda at the DHCFP Web site (www.dhcfp.nv.gov)

Posting of the Agenda will be at the Nevada Medicaid Central offices in Carson City and Las Vegas; Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a copy of the action items will be mailed to you or they may be reviewed Monday through Friday from 9:00 a.m. until 5:00 p.m., or at the meeting. Please call at least one day ahead for an appointment for document review. Written comments on the proposed changes may be sent to the DHCFP, 1100 E. William Street, Suite 102, Carson City, NV 89701.

All persons that have requested in writing to receive the Open Meeting Agenda have been duly notified by mail or e-mail.

Anyone presenting documents for consideration during the public comment portion of the meeting must provide sufficient copies for each member of the committee and the official record. Copies are to be distributed at the time of the meeting and should be provided at both meeting locations; DHCFP or its contractor will not distribute public comment information or materials prior to the public meeting.